Mark Alan Goldberg, EVP, Medical & Reg. Strategy at SYNAGEVA BIOPHARMA CORP (GEVA), sold 21,597 shares at $80.00 ($1.7M) on 2014-06-11, disclosed to the SEC on 2014-06-12.
Scheduled sale ($1.7M) by EVP, Medical & Reg. Strategy under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |